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1. Introduction 
Initiation of the classical pathway of complement 
involves the interaction and activation of the Cl com- 
plex with an activator such as immune aggregates [ 11. 
Component C4, which is composed of 3 chains (cr, /3 
and y ofMr 93 000,75 000 and 33 000, respectively 
[2]) is then activated by the Ci complex by the cleav- 
age of the C4a peptide (M, - 8000) from the N-ter- 
minus of the o-chain to yield C4b. The freshly acti- 
vated C4b can bind covalently, via a reactive glutamyl 
group in its a’chain, to a variety of surfaces by the 
formation of an ester, or perhaps amide, band [3-S] 
in a similar manner to that described for C3b binding 
[6-81. The C4b can be utilized in the formation of 
the C3 converting enzyme, the complex C 142. The 
control of this complex is partly mediated by the C4- 
binding protein (C4bp) which interacts with both the 
surface bound, and soluble, forms of C4b, acting as a 
cofactor in the rapid cleavage of the of-chain of C4b, 
at 2 positions, by the enzyme C3b/C4b inactivator 
[9-121. 
separated by ionexchange chromatography and both 
have cofactor activity [ 141. The y-carboxyglutamic 
acid-containing, vitamin Kdependent, protein S 
appears to form a strong complex with a major por- 
tion of the M, 590 000 band of C4bp found in serum 
[ 151. It was also found that C4bp isolated from a 
supernatant, which lacked protein S, was composed 
of one band, under non-reducing conditions, which 
appeared equivalent to the M, 540 000 band in [ 131. 
Here, the N-terminal sequence of 36 residues of a 
preparation of C4bp, which gave both high M, bands 
on SDS-PAGE under non-reducing conditions, is 
compared with the sequence of 13 residues obtained 
for C4bp from a study of the C4bp-protein S complex 
[ 151. The limited proteolysis of C4bp by trypsin, 
which generates discrete fragments of Mr 39 OOO- 
36 000 is also described. This procedure should be 
useful in future structural studies and also in the 
study of the interaction between C4bp and C4b since 
the trypsin-treated C4bp retains its cofactor activity. 
Human C4bp has been reported to give 2 closely 
spaced bands of M, - 590 000 and - 540 000 on 
SDS-PAGE using non-reducing conditions, and a 
single band of MI - 7 5 000 upon reduction [ 131. The 
2 bands, seen under non-reducing conditions, can be 
2. Materials and methods 
Abbreviations: SDS-PAGE, sodium dodecyl sulphate-poly- 
acrylamide gel electrophoresis; EDTA, ethylene diamine tetra- 
cetic acid; DFP, diisopropylphosphorofluoridate; SBTI, soy- 
bean trypsin inhibitor;IgG, immunoglobulin G; IgM, immuno- 
globulin M; PTH, phenylthiohydantoin; Fluram, fluorescamine 
Nomenclature: The nomenclature of complement components 
is that recommended by the World Health Organisation 
(1968); a bar over a component indicates that the component 
is activated 
Human C4bp was prepared from outdated plasma 
by polyethylene glycol precipitation, salt gradient 
elution from Bio-Rex-70, DEAE-Sephadex A-50, 
heparin-Sepharose and DEAE-Sephacel and finally 
gel-filtration on Sephacryl S-300. The polyethylene 
glycol precipitation and heparin-Sepharose chroma- 
tography were performed as in [ 161 and the DEAE- 
Sephadex A-50 and Bio-Rex-70 steps were performed 
as in [ 131. Ion-exchange chromatography on DEAE- 
Sephacel was performed as follows: C4bp from 
heparin-Sepharose was concentrated to 15 ml by 
ultrafiltration and dialysed against 70 mM NaCl, 
20 mM Tris--HCl, 2 mM EDTA (pH 7.4). The dialysed 
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sample (15 mlAzsc = 1 .OS) was applied to a column 
(1.3 X 14 cm) of DEAE-Sephacel equilibrated with 
70 mM NaCl, 20 mM Tris-HCl, 2 mM EDTA (pH 
7.4) at a flow rate of 30 ml/h. After washing with 
80 ml of the same buffer, the protein bound to the 
column was eluted with a linear gradient (chamber 1, 
200 ml equilibrating buffer; chamber 2,200 ml 
equilibrating buffer made 0.4 M with respect to NaCl) 
(fig.la). Gel-filtration was performed by application 
of a concentrated sample (7 ml Azse = 1.86) of C4bp, 
from DEAE-Sephacel, to a column (3 X 90 cm) of 
Sephacryl S-300 eqilibrated with 140 mM NaCl, 
20 mM Tris-HCl, 2 mM EDTA (pH 7.4) at a flow 
rate of 20 ml/h. To remove traces of IgM a Sepharose 
anti-@! column was prepared (using the IgG fraction 
of a rabbit antiserum raised against a human myeloma 
IgM) and run as described in [ 171. The ability of 
C4bp fractions, and the trypsin-digested C4bp, to act 
as a cofactor in the splitting of C4b by C3b/C4b inac- 
tivator was assessed by SDS-PAGE using weight 
ratios of C4bp:C4b:C3b/C4b inactivator of 0.6: 1 .O: 
0 .O 1. The preparations of C4b and C3b/C4b inacti- 
vator were supplied by Dr R. D. Campbell (Oxford) 
and Dr L.-M. Hsiung (Oxford). 
Samples and marker proteins for SDS-PAGE were 
prepared and run as in [ 181. Amino acid analysis and 
hexosamine analysis was performed as in [ 181. Human 
C4bp was reduced and alkylated (with iodo[2-14C]- 
acetic acid) and subjected to automated Edman 
degradation in a Beckman 890~ sequencer using the 
procedures given in [ 181. At step 13 in the sequencer 
run the sample was reacted with Fluram as in [ 191. 
Human C4bp was treated with trypsin at a variety 
of substrate-to-enzyme ratios (from 30/l-1000/1, 
w/w) in 0.2 M NH4HC0a (pH 8.0) at 25’C for 16 h. 
The digestion was stopped by the addition of DFP 
in the preparative procedures, or SBTI in the analyti- 
cal procedures. 
3. Results 
3.1. Am’fica tion 
The yield of C4bp was -12 mg/l of plasma and 
traces of IgM could be removed from the preparation 
by passage down a Sepharose anti-&M column. The 
purified C4bp behaved as a single symmetrical peak 
on Sephacryl S-300 (being eluted between 190-- 
120 ml, in a similar position to that of human IgM) 
but appeared heterogeneous on ion-exchange chro- 
matography on DEAE-Sephacel (fig.la). There were 
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Fig.1. (a) Ion-exchange chromatography of C4bp (15 ml 
A $a0 = 1.05), from heparin-Sepharose, on a column (1.3 X 
14 cm) of DEAE-Sephacel. The protein bound to the column 
was eluted with a linear salt gradient as described in the text: 
4.3 ml fractions were collected. (b) SDS-PAGE, on a 7% slab 
gel, of non-reduced samples from fractions 41,43,46,48 and 
52 are shown in tracks 3,4,5,6 and 7, respectively. All these 
samples gave a single band, on reduction, as shown in track 2. 
A non-reduced sample of the material applied to the column 
is shown in track 8. 
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at least 3 peaks of protein as judged by the Azse but 
each peak had the same composition as judged by 
SDS-PAGE (figlb) in non-reducing, and reducing, 
conditions. The non-reduced samples gave 2 closely 
spaced bands, which stained with about the same 
intensity, in the Mr 540 000-590 000 region, while 
all the reduced samples gave a single band of apparent 
Mr - 75 000 (fig.lb). Each peak from the DEAE- 
Sephacel showed C4bp activity as judged by its ability 
to act as a cofactor in the splitting of C4b by C3b/C4b 
inactivator. 
All the fractions from DEAE-Sephacel containing 
C4bp, as judged by cofactor activity measurements 
and SDS-PAGE, were pooled and this material, after 
gel-filtration on S-300, was used for amino acid anal- 
ysis, hexosamine analysis, N-terminal sequence deter- 
mination and limited proteolysis by trypsin. 
3.2. Amino acid and hexosamine compositions 
The ammo acid composition found for human 
C4bp was very similar to that reported in [ 161 except 
for a higher halfcystine value (6.17% vs 4.89%) and 
a lower glutamic acid value (10.99% vs 13.65%) 
(table 1). The C4bp was found to contain 3 5% (w/w) 
glucosamine and no galactosamine. 
Table 1 
Amino acid composition of human C4bpa 
Residue Residues/l00 residues 
Asx 7.87 
Thr 6.38 
Ser 7.96 
Glx 10.99 
Pro 7.62 
CJY 7.05 
Ala 3.39 
l/2 Cysb 6.17 
Val 5.97 
Met 0.87 
Be 4.38 
Leu 6.11 
Tyr 4.35 
Phe 3.08 
His 2.81 
LYS 5.71 
A% 5.23 
Trp 3.95 
a Samples were hydrolysed in 5.7 N HCl for 24,48 and 72 h 
at 110°C under vacuum and the serine and threonine values 
were estimated by extrapolation to zero time 
b Half-cystine was estimated as S-carboxymethylcysteine 
1 10 
Asn-Cys-Gl/-Pro-Pro-Pro-Thr-Leu-Ser-Phe-.Aln-Ala-Pro-Met-Asp- 
20 30 
-X-Thr-I.eu-Thr-Glu-Thr-Arg-Phe-Lys-Thr-Giy-Thr-Thr-Leu-Lys- 
36 
-Thr-Thr-Cys-Leu-Pro-Gly- 
Fig.2. N-Terminal amino acid sequence of human C4bp. 
3.3. N-Terminal amino acid sequence 
Automated N-terminal amino acid sequence anal- 
ysis of 45 nmol reduced and alkylated C4bp gave a 
single unambiguous sequence for 36 residues (fig.2). 
The N-terminal amino acid found was asparagine, 
and the yield of PTH-asparagine on the first cycle 
was -6O%, of that expected. A repetitive yield of 
97% was obtained during the run based on the yield 
of leucine at positions 8, 18,29 and 34. There was 
very little background, or ‘carry-over’, of PTH-amino 
acids during the run, however the identification of 
PTH-amino acids beyond cycle 13 was probably 
enhanced by the treatment of the sample with Fluram 
at cycle 13. 
3.4. Limited pro teolysis of C4bp by trypsin 
Treatment of C4bp with trypsin (50/l, w/w) in 
0.2 M NH_,HCOa (pH 8.0) at 25°C for 16 h yielded a 
molecule which behaved in an identical fashion to the 
untreated molecule on gel-filtration on Sephacryl 
S-300 and with respect to its mobility on SDS-PAGE 
in non-reducing conditions (fig.3). On reduction of 
the trypsin-digested C4bp, and examination on SDS- 
PAGE, it could be seen that all the intact (M, 75 000) 
chain had been converted to 2 major fragments with 
app. M,-values of 37 500 and 36 000 (fig.3) plus some 
low Mr material. Using milder conditions of trypsin 
digestion (fig.4) the 37 5OOM, fragment could be 
seen to be generated via a fragment of app. Mr 39 000 
The Mr 37 500 and 36 000 fragments were separated 
from low M, peptide material, after reduction and 
alkylation of the trypsin digested C4bp, by gel filtra- 
tion on Sephadex G-50 (superfine) in 0.2 M NHaHCOa 
(pH 8.0). N-Terminal sequence analysis of a mixture 
77 
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Fig.3. SDS-PAGE, on a 10% slab gel, of C4bp incubated at 
25°C for 16 h in 0.2 M NH,HCO, with (+) and without (-) 
trypsin at 50/l (w/w) substrate/enzyme. DFP was added at 
16 h to inhibit further digestion. 
of the M, 37 500 and 36 000 fragments indicated that 
at least the N-terminal 40 residues of the intact chain 
of C4bp are cleaved off during limited proteolysis by 
trypsin. 
The trypsindigested C4bp, which showed no 
intact Mr 75 000 chain under reducing conditions 
(fig.3) still retained its ability to behave as a cofactor 
for the breakdown of C4b by C3b/C4b inactivator. 
4. Discussion 
The C4bp preparation used in this study appeared 
to be composed of about equal amounts of the Ikfr 
540 000 and 590 000 bands [ 131 when examined on 
Fig.4. SDS-PAGE, on a 10% slab gel, of C4bp treated with 
trypsin at 25°C for 16 h in 0.2 M NH,HCO,. Ratios of 100/l, 
200/l, 400/l and 800/l (w/w) C4bp/trypsin are shown in 
the first 4 tracks and a control sample (-) incubated without 
trypsin is shown in track 5. All the samples are reduced. The 
equivalent non-reduced samples all showed the same gel pat- 
tern as undigested C4bp. SBTI was added at 16 h to inhibit 
further digestion. 
SDS-PAGE in non-reducing conditions (fig.lb). Only 
a very minor band could be seen in the M, 70 000 
region, in non-reducing conditions, even with a high 
loading of the C4bp preparation (fig.lb, tig.3). This 
indicated that if protein S, which has been shown to 
copurify with the Mr 590 000 band [ 15 1, was present 
then the amount was low (<5%, assuming equal 
intensity of staining by the Mr 75 000 chain of C4bp 
and protein S). The results of the amino acid sequence 
analysis (tig.2) confirm, and extend, the N-terminal 
sequence of 13 residues obtained for C4bp from the 
sequence of analysis of a mixture of C4bp and pro- 
tein S [ 151. The yield of F’TH-amino acids, in first 
few cycles of the sequence analysis of C4bp, indicate 
that C4bp is composed of a single type of polypeptide 
78 
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chain and also that it was unlikely that any other 
polypeptide chain, with a free N-terminal amino acid, 
was present at a level >5% of that of the C4bp chain. 
The amino acid composition found for C4bp 
(table 1) is very similar to the only other composition 
published for this protein [ 161 and the hexosamine 
analysis has established that C4bp has a relatively 
high (3.5%) glucosamine value. The difference between 
the 2 forms of C4bp with app. M,-values of 590 000 
and 540 000 is unknown but could be related to the 
carbohydrate content, or the number ofM, 75 000 
chains present. The presence of 2 forms of C4bp may 
account for some of the apparent heterogeneity seen 
on ion-exchange chromatography seen in fig.la and 
reported in [13,14]. 
It is of interest that the trypsin-treated C4bp 
retained its cofactor activity and behaved in an identi- 
cal fashion to the untreated molecule on gel-filtration, 
and on SDS-PAGE under non-reducing conditions 
(fig.3) when it had been split in at least 2 positions 
(fig.4) in each of its Mr 75 000 chains. The trypsin- 
treated molecule could therefore be useful in studies 
designed to determine which portion of the C4bp 
molecule interacts closely with C4b. 
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